Stock Market Today, March: CytomX Surges on Positive Data
CytomX Therapeutics delivered a sharp rally after promising Phase 1 data for its colorectal cancer program. This arti...
Looking for short term gigs? Discover where to find quick cash options that fit your schedule.
25,797 articlesCytomX Therapeutics delivered a sharp rally after promising Phase 1 data for its colorectal cancer program. This arti...
One staffing stock plunged 56% in the last year, but a large new stake worth almost $10 million could signal a forthc...
A high-profile rift between two longtime mentors-turned-critics shines a light on how money, branding, and risk manag...
NVIDIA leads AI chips while MICRON powers AI memory. This in-depth comparison helps investors decide the better buy: ...
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Barclays lifts Atlassian price target to $112, signaling growing confidence in the company’s ARR trajectory and enter...
A clear, practical look at Expedia's Q1 2026 earnings, what drove results, and what to watch next. Learn the segments...
When Palantir reveals new AI-focused capabilities, Nvidia stock often faces a unique set of pressures. This guide bre...
Investors are watching PLBY closely as plby (plby) 2026 earnings unfold. This article breaks down Q1 results, evaluat...
Pfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
The kiplinger letter spots trap emerges as a focal point in retirement planning as 401(K) plans weigh adding private ...
A new 2026 survey shows Gen Z is leaning into financial independence, saying ‘no’ more often to costly experiences an...